Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 5/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30606424 | 1.00 | NR1H2 (0.38) | NR1H2NR1H3LIPEDYRK1A | |
| SCHEMBL623299 | 0.79 | KDM4E (0.39) | NR1H2NR1H3LIPE | |
| SCHEMBL15676427 | 0.78 | KDM4E (0.38) | NR1H2NR1H3LIPE | |
| SCHEMBL26658314 | 0.77 | NR1H2 (0.38) | NR1H2NR1H3LIPE | |
| SCHEMBL30606415 | 0.77 | NR1H2 (0.38) | NR1H2NR1H3LIPE | |
| SCHEMBL25332377 | 0.75 | CYP1A2 (0.34) | NR1H2NR1H3LIPE | |
| SCHEMBL15535603 | 0.75 | ALPL (0.34) | DYRK1A | |
| SCHEMBL25427826 | 0.70 | LPL (0.37) | NR1H2NR1H3LIPE | |
| SCHEMBL12204024 | 0.70 | HPGD (0.40) | DYRK1A | |
| SCHEMBL1192101 | 0.70 | LPL (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595255-B2 | Heteroaryl-substituted imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20230373978-A1 | HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373978-A1 | HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES | F3, ABL1, CFTR | NR1H2 1950/4885NR1H3 1791/4885LIPE 4214/4885 |
| US-12595255-B2 | Heteroaryl-substituted imidazole derivatives | CLIC1, CYP2B6, CYP2D6 | NR1H2 1840/4885NR1H3 1472/4885LIPE 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.